Scotland's prescription co-codamol supply is running low, with potential shortages until June 2026. This is due to a delay in the Indian government's authorization of codeine-based active pharmaceutical ingredients (APIs) required for co-codamol production. The Scottish government is working closely with the UK government to resolve the issue and ensure patients receive accurate information and clear advice. While the UK government assures that the 'vast majority' of licensed medicines are in good supply, there are concerns about the impact on patients. The situation highlights the importance of medicine supply chains and the potential consequences of disruptions. Patients are advised not to contact their GP practices or community pharmacies, as alternative treatment options are being identified and offered.
